Hemogenyx Pharmaceuticals Company Description
Hemogenyx Pharmaceuticals Plc, a clinical-stage biotechnology company, focuses on the discovery, development, and commercialization of treatments for blood cancer.
The company’s lead product candidate is the HG-CT-1 therapy for the treatment of relapsed or refractory acute myeloid leukemia.
It also develops chimeric bait receptor to treat viral infections derived and for certain cancer and neurological conditions; and CDX bi-specific antibody which eliminates hematopoietic stem cells/hematopoietic progenitors in a patient using bi-specific antibodies; and therapies for the improvement of bone marrow and blood stem cell transplant procedures.
Hemogenyx Pharmaceuticals Plc was incorporated in 2013 and is headquartered in London, the United Kingdom.

Country | United Kingdom |
Founded | 2013 |
Industry | Biotechnology |
Sector | Healthcare |
Employees | 16 |
CEO | Vladislav Sandler |
Contact Details
Address: 6 Heddon Street London, W1B 4BT United Kingdom | |
Website | hemogenyx.com |
Stock Details
Ticker Symbol | HEMO |
Exchange | London Stock Exchange |
Fiscal Year | January - December |
Reporting Currency | GBP |
ISIN Number | GB00BYX3WZ24 |
SIC Code | 2836 |
Key Executives
Name | Position |
---|---|
Dr. Vladislav Sandler Ph.D. | Co-Founder, Chief Executive Officer and Director |
Alexis M. Sandler J.D. | Independent Co-Founder and Non-Executive Director |
Dr. Koen Van Besien M.D., Ph.D. | Clinical Advisor and Medical Director |
Ben Harber | Company Secretary |